The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic ...

The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

GSK respiratory, immunology and inflammation research and development (R&D) global head and senior vice-president Kaivan ...

The U.S. Food and Drug Administration has approved Nucala as a supplementary treatment for elderly individuals with severe ...

FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

At ATS 2025, data from the Phase III MATINEE trial reinforced the efficacy of Nucala in reducing exacerbations in COPD ...

Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of lung ...

GSK’s blockbuster respiratory drug Nucala was approved Thursday for certain patients with chronic obstructive pulmonary ...

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil ...